Andreas Stolle, PhD Vice President, API Process Development Services Patheon

Andreas Stolle, PhD, Vice President, API Process Development Services, Patheon, discussed how the company is integrating its most recent acquisition into its active pharmaceutical ingredient (API) network at the DCAT Member Company Announcement Forum that was held Monday March 20 at DCAT Week ’17.

In February 2017, Patheon completed its acquisition of an API manufacturing facility in Florence, South Carolina from Roche Holdings, Inc. Patheon has begun integrating the site into its manufacturing network.

The site adds a 300,000 square-foot facility with manufacturing capacity for APIs ranging from development to commerical-scale manufacturing. With the addition of the site, the company also expands its capacity for manufacturing highly potent compounds and adds capabilities to support solid-state chemistry, micronization (small and large), and future commercial spray drying. The facility features production space with reactors ranging from 50-11,000 liters with capabilities of producing multiple products simultaneously.

Stolle said that the Florence site will serve as Patheon’s flagship US API operation for commercial-scale and mid-scale API production and will also enhance Patheon’s emerging pharma presence in the US market. This acquisition is the company’s sixth in the last five years and supports the company’s strategy to create an integrated, end-to-end provider of pharma development and manufacturing services.